Positive Health Online
Your Country
![[Image: http://www.abundanceandhealth.co.uk]](/img/original/BannerAvatar/2836.df7d2315253110ff5b3a566f94871f99.jpg "http://www.abundanceandhealth.co.uk")
![[Image: http://www.balens.co.uk]](/img/original/BannerAvatar/2148.50367fa908013fae0a7f1a171543ef92.jpg "http://www.balens.co.uk")
![[Image: https://www.water-for-health.co.uk/]](/img/original/BannerAvatar/4046.12831f50177f8848ee87b8e94411d6b3.jpg "https://www.water-for-health.co.uk/")
![[Image: http://www.drsgoodman.com/books-goodman/52-nutrition-and-cancer]](/img/original/BannerAvatar/1859.1296090fd8385e7ceff51c8011559097.jpg "http://www.drsgoodman.com/books-goodman/52-nutrition-and-cancer")
Research: LAST and co-workers,
Listed in Issue 94
Abstract
LAST and co-workers, Cancer Research UK Medical Oncology Unit, Department of Medical Oncology, St Bertholomew's Hospital, London EC1M 6BQ, UK, kim.last@cancer.org.uk, have found that serum selenium status on presentation predicts for overall survival, dose delivery, and first treatment response in aggressive non-Hodgkin's lymphoma.
Background
Background: The concentration of selenium in blood at the time of presentation in hospital was thought to predict the course and outcome of the disease in non-Hodgkin's lymphoma patients.
Methodology
Methods: Patients received anthracycline-based chemotherapy, radiotherapy, or both. The total selenium content of their blood serum was analysed in samples taken at presentation.
Results
Results: Serum selenium concentrations ranged from 0.33 to 1.51 micromol per litre (average 0.92, compared to UK adult reference range of 1.07 to 1.88 micromol per litre). Serum selenium concentrations correlated with performance status. Multivariate analysis revealed that increased dose delivery correlated positively with younger age, advanced stage, and higher serum selenium. There was also a positive correlation between selenium and response (odds ratio 0.62) and achievement of long-term remission after first treatment. Selenium was positively predictive of overall survival on multivariate analysis.
Conclusion
Conclusions: Serum selenium concentration at presentation is a prognostic factor, predicting positively for dose delivery, treatment response, and long-term survival in aggressive non-Hodgkin's lymphoma. It remains to be investigated if selenium supplementation offers a novel treatment strategy for this frequently curable cancer.
References
Last KW, Cornelius V, Delves T, Sieniawska C, Fitzgibbon J, Norton A, Amess J, Wilson A, Rohatiner AZS, Lister TA. Presentation serum selenium predicts for overall survival, dose delivery, and first treatment response in aggressive non-Hodgkins' lymphoma. Journal of Clinical Oncology 21 (12): 2335-2341, Jun 2003.
